#Keynote 189 trial#
#Keynote 189 plus#

KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB, IIC, or III melanoma following complete resection. KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma. Selected KEYTRUDA ® (pembrolizumab) Indications in the U.S.

The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient's likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers. There are currently more than 1,600 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. Merck has the industry’s largest immuno-oncology clinical research program. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.

KEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. Of patients with no metastases at CRPC diagnosis, 33% are likely to develop metastases within two years.Ībout KEYTRUDA ® (pembrolizumab) injection, 100 mg Approximately 10-20% of patients with advanced prostate cancer will develop CRPC within five years, and at least 84% of these patients will have metastases at the time of CRPC diagnosis. In patients with mCRPC, their prostate cancer grows and spreads to other parts of the body, despite the use of androgen-deprivation therapy to block the action of male sex hormones. Development of prostate cancer is often driven by male sex hormones called androgens, including testosterone. Prostate cancer is the second most common cancer in men globally and is associated with a significant mortality rate.

#Keynote 189 trial#

Additionally, last month, Merck entered into a global development and commercialization agreement with Orion Corporation for Orion’s investigational candidate ODM-208, which is currently being evaluated in a Phase 2 clinical trial for the treatment of patients with mCRPC.Ībout metastatic castration-resistant prostate cancer Merck has an extensive clinical development program evaluating KEYTRUDA, Merck’s anti-PD1 therapy, as monotherapy and in combination with other anti-cancer therapies in prostate cancer, including the Phase 2 trials KEYNOTE-199 and KEYNOTE-365 and the Phase 3 registrational trials KEYNOTE-641 and KEYNOTE-991. Merck has a strong commitment to the development of new treatment options for people with prostate cancer. 'We are grateful to the patients and investigators for their participation in this study.'

Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. We will continue to advance our clinical development program to evaluate KEYTRUDA-based combinations and novel candidates for patients with this disease,' said Dr. 'Results from this study serve as an important reminder that metastatic prostate cancer remains very difficult to treat, and more research is needed. Results will be presented at an upcoming medical meeting. The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies.

#Keynote 189 plus#

In the study, there were modest trends toward an improvement in both OS and rPFS for patients who received KEYTRUDA plus chemotherapy compared with chemotherapy alone however, these results did not meet statistical significance per the pre-specified statistical plan. RAHWAY, N.J., August 03, 2022-( BUSINESS WIRE)-Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-921 trial evaluating KEYTRUDA in combination with chemotherapy (docetaxel) compared to chemotherapy alone did not meet its dual primary endpoints of overall survival (OS) and radiographic progression-free survival (rPFS) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).